MindMed (MNMD.Q) announced they are appointing Dr. Maurizio Fava to their Scientific Advisory Board.
Dr. Fava obtained his medical doctorate from the University of Padova School of Medicine, and went on to residency training in psychiatry at Massachusetts General Hospital where he founded and was Director of the hospital’s Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, Dr. Fava founded the Massachusetts General Hospital’s Psychiatry Clinical Trials Network and Institute (CTNI), where he currently acts as their Executive Director.
Through his role at the DCRP, Dr. Fava has secured more than $120,000,000 of funding from the National Institute of Health. He has also authored or co-authored more than 800 original articles published in medical journals.
This combination of knowledge of depression and clinical trials makes him an ideal member of a scientific advisory board. Through his role at the DCRP, Dr. Fava has secured more than $120,000,000 of funding from the National Institute of Health. He has also authored or co-authored more than 800 original articles published in medical journals.
“We are incredibly excited to welcome Dr. Fava as the newest member of our Scientific Advisory Board. His wisdom and experience as a thought leader in psychiatry are unparalleled and his insights and guidance will be invaluable. I look forward to working closely with Dr. Fava and the entire Scientific Advisory Board as we advance our mission of delivering psychedelic-inspired therapies to patients in need,” stated Robert Barrow, CEO of MindMed.
For astute regular Equity Guru readers, Fava’s name should ring a few bells, as I wrote about his appointment to Cybin’s scientific advisory board. Cybin and MindMed have similar aims, and so someone qualified for one of their scientific boards is likely to be qualified for the other.
“I am delighted to join MindMed’s Scientific Advisory Board. Massachusetts General Hospital has recently launched a new Center for the Neuroscience of Psychedelics to better understand the drugs’ effects on the brain, their mechanisms, and potential for therapeutic purposes. MindMed’s focus on psychedelic medicine is certainly aligned with the scientific interests of our department,” stated Dr. Fava.
Fava adds experience in psychiatry and clinical trials to an already experienced group.
Dr. Fava is joining a large scientific advisory board with a lot of different specialties. The scientific advisory board has members from a range of scientific backgrounds, from neuroscience to chemistry to psychiatry and behavioural science. Fava adds experience in psychiatry and clinical trials to an already experienced group.
“I am very excited that Dr. Fava has joined our Scientific Advisory Board. His extensive experience in designing rigorous and sophisticated clinical trials will accelerate MindMed’s efforts to initiate efficient clinical trials that provide clear answers about the therapeutic effectiveness of MindMed’s innovative treatment regimens,” added Dr. Robert Malenka, MindMed’s Scientific Advisory Board Chair.
Following the announcement, MindMed’s share price is down 13 cents and is currently trading at $3.46.